Graphene 3D Lab Inc(British Columbia)
Change company Symbol lookup
Select an option...
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
ED Consolidated Edison Inc
CLS Celestica Inc
HNHAF Hon Hai Precision Industry Co Ltd
Go

Materials : Chemicals | Small Cap Growth
Company profile

Graphene 3D Lab Inc. is engaged in the business of developing, manufacturing and marketing polymer nanocomposite graphene-based materials. The Company is also engaged in the development, manufacturing and marketing of graphene and other two-dimensional (2D) crystals, as well as composites based on these nanomaterials. These materials have a spectrum of commercial, research and military applications. The three-dimensional (3D) printing division offers a portfolio of specialty fused filament fabrication filaments. Its Industrial Materials Division develops graphene-infused polymers targeted for automotive, robotics, drone, aerospace and military industries. The Company, through Graphene Laboratories Inc., is engaged in manufacturing and retailing of graphene and advanced materials. It markets its materials to various industries, including the aerospace, manufacturers of medical prosthetics, as well as the various types materials for 3D printing, such as fused filament fabrication.

Closing Price
$0.0975
Day's Change
0.004 (4.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.101
Day's Low
0.0876
Volume
(Light)
Volume:
279,281

10-day average volume:
605,165
279,281

ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment

4:00 am ET November 23, 2020 (PR Newswire) Print

ISD Immunotech (ISD), which is developing targeted therapies for severe autoimmune diseases, today announces it has entered into a strategic research collaboration with Biogen Inc., Cambridge, MA, USA (Nasdaq: BIIB).

ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE). Severe lupus is an autoimmune disease that can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain, which if left untreated can lead to kidney failure and cardiovascular mortality. There are up to 1.5 million people in the US alone with lupus. ISD 017 is a proprietary and novel peptide therapeutic which is an inhibitor of the stimulator of interferon genes (STING) pathway. The STING pathway has recently been shown to play a central role and to be overactivated in severe lupus, a condition with a highly underserved patient population.

Novo Seeds, the early stage investment and company creation arm of Novo Holdings, has provided additional funding to accelerate development of ISD0 017. Jeroen Bakker from Novo Seeds will join the Board.

"We are pleased that Biogen, a leader in drug development has selected ISD Immunotech as its collaboration partner. With its recent positive Phase 2 study results for CLE and SLE, Biogen's interests and competencies complement ISD Immunotech's areas of expertise in lupus, STING biology and peptide drug development," said Tara Heitner, CEO of ISD Immunotech. "This collaboration underscores the quality of our therapeutic program and recognizes the importance of STING pathway overactivation in severe SLE. Together with Biogen, we aim to deliver one of the first new therapies to treat severe SLE in over 50 years."

Jeroen Bakker, Principal at Novo Seeds, commented: "ISD Immunotech is an excellent example of our strategy to support and build high-potential companies founded on world class science in the Nordics. ISD has identified a novel STING pathway inhibitor which is highly differentiated from other programs in development. Based on promising preclinical data we believe this therapy can address an underserved population of severe SLE patients. We are pleased that ISD has attracted Biogen as a strategic collaboration partner and see this as further validation of ISD's novel approach to treating severe SLE. We look forward to the ongoing collaboration with ISD and Biogen."

About the STING Pathway

STING (stimulator of interferon genes) is a key mediator of innate immunity and the STING pathway has been shown to be overactivated in severe SLE and a central mediator of all downstream events leading to disease symptoms. When overstimulated, as in the case of severe SLE, STING induces the expression of type I interferon and other pro-inflammatory cytokines which activate immune cells leading to severe organ damage complications.

About ISD Immunotech

ISD Immunotech is a private preclinical biotech startup focusing on the development of a peptide therapeutic, ISD-017, which uniquely blocks all aspects of STING pathway overactivation in severe SLE. The company, headquartered in Copenhagen, is a spinout of Aarhus University, Denmark, which is an academic center of excellence in STING biology. ISD Immunotech is run by a team of seasoned biotech and pharma executives with decades of peptide R&D experience. The company is supported by world class academic and clinical advisors with deep insight into STING biology, animal disease models and clinical lupus research. www.isd-immunotech.com

About Novo Holdings A/S:

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. www.novoholdings.dk

https://c212.net/c/img/favicon.png?sn=IO99511&sd=2020-11-23

View original content:http://www.prnewswire.com/news-releases/isd-immunotech-a-novo-seeds-portfolio-company-enters-strategic-research-collaboration-for-the-development-of-a-novel-lupus-treatment-301178103.html

SOURCE Novo Holdings

https://rt.prnewswire.com/rt.gif?NewsItemId=IO99511&Transmission_Id=202011230400PR_NEWS_USPR_____IO99511&DateId=20201123

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.